Form 144 TYRA BIOSCIENCES For: 26 June
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Tyra Biosciences Inc (TYRA)
Tyra Biosciences Inc stock price live, this page displays NASDAQ TYRA stock exchange data. View the TYRA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Tyra Biosciences Inc real time stock price chart below.
What Is the Tyra Biosciences Inc Stock Price Today?
The Tyra Biosciences Inc stock price today is 32.15.
What Is the Stock Symbol for Tyra Biosciences Inc?
The stock symbol for Tyra Biosciences Inc is "TYRA."
What Stock Exchange Does Tyra Biosciences Inc Trade On?
Tyra Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Tyra Biosciences Inc a Good Stock to Buy?
Determining whether Tyra Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TYRA quote. (ISIN: US90240B1061)
What Is the Tyra Biosciences Inc Stock Price Today?
The Tyra Biosciences Inc stock price today is 32.15.
What Is the Stock Symbol for Tyra Biosciences Inc?
The stock symbol for Tyra Biosciences Inc is "TYRA."
What Stock Exchange Does Tyra Biosciences Inc Trade On?
Tyra Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Tyra Biosciences Inc a Good Stock to Buy?
Determining whether Tyra Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TYRA quote. (ISIN: US90240B1061)
NASDAQ
Currency in USD
32.15
+1.04(+3.34%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.06
32.59
52 wk Range
9.96
40.65
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.0632.59
52 wk Range
9.9640.65
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TYRA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
51.97
Upside
+61.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Tyra Biosciences receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Tyra Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 144 TYRA BIOSCIENCES For: 26 June
- Investing.com
- Tyra Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Tyra Biosciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 51.97
(+61.64% Upside)
Earnings
Latest Release
May 13, 2026
EPS / Forecast
-0.64 / -0.59
Revenue / Forecast
-- / --
Compare TYRA to Peers and Sector
Metrics to compare | TYRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTYRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.6x | −13.2x | −0.3x | |
PEG Ratio | 0.42 | −0.40 | 0.00 | |
Price/Book | 5.0x | 6.6x | 2.6x | |
Price / LTM Sales | - | 375.0x | 2.9x | |
Upside (Analyst Target) | 72.0% | 68.1% | 56.7% | |
Fair Value Upside | Unlock | −17.0% | 10.2% | Unlock |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Tyra Biosciences (TYRA) Stock Price Today?
The Tyra Biosciences stock price today is 32.15 USD.
What Stock Exchange Does Tyra Biosciences Trade On?
Tyra Biosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Tyra Biosciences?
The stock symbol for Tyra Biosciences is "TYRA."
What Is the Tyra Biosciences Market Cap?
As of today, Tyra Biosciences market cap is 1.85B USD.
What Is Tyra Biosciences's Earnings Per Share (TTM)?
The Tyra Biosciences EPS (TTM) is -2.18.
When Is the Next Tyra Biosciences Earnings Date?
Tyra Biosciences will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is TYRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Tyra Biosciences Stock Split?
Tyra Biosciences has split 0 times.
How Many Employees Does Tyra Biosciences Have?
Tyra Biosciences has 87 employees.
What is the current trading status of Tyra Biosciences (TYRA)?
As of Jul 30, 2026, Tyra Biosciences (TYRA) is trading at a price of 32.15 USD, with a previous close of 31.11 USD. The stock has fluctuated within a day range of 31.06 USD to 32.59 USD, while its 52-week range spans from 9.96 USD to 40.65 USD.
What Is Tyra Biosciences (TYRA) Price Target According to Analysts?
The average 12-month price target for Tyra Biosciences is 51.97 USD, with a high estimate of 59.62 USD and a low estimate of 42 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +61.64% Upside potential.
What Is the TYRA Premarket Price?
TYRA's last pre-market stock price is 31.51 USD. The pre-market share volume is 171.00, and the stock has decreased by 0.40, or 1.29%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.